FDA Approves Short-Acting Neutropenia Drug tbo-filgrastim (Sicor)

“Supportive care products, such as tbo-filgrastim, reduce or allow for more rapid recovery from side effects of cancer treatments,” Richard Pazdur, MD, director of the FDA Office of Hematology and Oncology Products, said in a statement.

The pivotal trial of tbo-filgrastim involved 348 women with advanced breast cancer treated with docetaxel and doxorubicin. Patients were randomized to G-CSF, placebo, or another form of G-CSF not available in the U.S. Recovery from chemotherapy-induced neutropenia occurred in an average of 1.1 days with tbo-filgrastim versus 3.8 days in the placebo group.

Read more:  FDA Approves Short Acting Neutropenia Drug


(click to sign the petition)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s